Abstract
Background
Moral injury affects a variety of populations who make ethically complex decisions involving their own and others’ well-being, including combat veterans, healthcare workers, and first responders. Yet little is known about occupational differences in the prevalence of morally injurious exposures and outcomes in nationally representative samples of such populations.
Objective
To examine prevalence of potentially morally injurious event (PMIE) exposure and clinically meaningful moral injury in three high-risk groups.
Design
Cross-sectional survey with responses weighted to national geodemographic benchmarks.
Participants
Combat veterans, healthcare workers, and first responders (N=1232) in the USA.
Main Measure
Moral Injury and Distress Scale (MIDS).
Key Results
Many combat veterans (49.3%), healthcare workers (50.8%), and first responders (41.6%) endorsed exposure to a PMIE. Clinically meaningful moral injury symptoms were endorsed by 6.5% of combat veterans, 7.3% of healthcare workers, and 4.1% of first responders. After adjusting for age, gender, race, and ethnicity, relative to first responders, combat veterans were more likely to endorse transgressing their values by what they did and healthcare workers were more likely to endorse witnessing others’ wrongful acts. Additionally, combat veterans (adjusted risk ratio (aRR) = 2.18, 95% confidence interval (95% CI) = 1.09, 2.16) and healthcare workers (aRR = 2.02, 95% CI = 1.03, 3.83) were over twice as likely to screen positive for clinically meaningful moral injury in comparison to first responders. No differences in exposures or outcomes emerged between combat veterans and healthcare workers.
Conclusions
Results from these nationally representative samples of three high-risk populations suggest that exposure to PMIEs is common and a sizable minority report clinically meaningful moral injury.
Topic
JGIM
Author Descriptions
Mental Health Service, San Francisco VA Health Care System, San Francisco, USA
Shira Maguen PhD
Department of Psychiatry and Behavioral Sciences, University of California San Francisco School of Medicine, San Francisco, USA
Shira Maguen PhD
Center for Mental Health Care & Outcomes Research, Central Arkansas VA, North Little Rock, USA
Brandon J. Griffin PhD
Psychiatric Research Institute, University of Arkansas for Medical Sciences, Little Rock, USA
Brandon J. Griffin PhD
Clinical Neurosciences Division, National Center for PTSD, West Haven, USA
Robert H. Pietrzak PhD
Department of Psychiatry, Yale School of Medicine, New Haven, USA
Robert H. Pietrzak PhD
Dissemination and Training Division, National Center for PTSD, Menlo Park, USA
Carmen P. McLean PhD
Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, USA
Carmen P. McLean PhD
Psychiatry Department, Geisel School of Medicine at Dartmouth, Lebanon, USA
Jessica L. Hamblen PhD
Executive Division, National Center for PTSD, White River Junction, USA
Jessica L. Hamblen PhD & Sonya B. Norman PhD
Psychiatry Department, University of California San Diego School of Medicine, La Jolla, USA
Sonya B. Norman PhD
Share
Related Articles
Clinical Utility of Routine Monoclonal Gammopathy Testing in the Evaluation of Peripheral Neuropathy
Abstract Background Peripheral neuropathy can be associated with certain monoclonal gammopathies; therefore,…
Starting Two or More Drugs Concurrently in Primary Care: How Often Is It Done, How Often Is It Needed?
Abstract Background There is growing awareness of the need for more cautious,…